Showing posts with label statistics. Show all posts
Showing posts with label statistics. Show all posts

Tuesday, August 2, 2011

Another Year, Another Burger

Today is my 41st birthday.

The Burger King
When I was a kid I used to be a member of the Hungry Jacks Club (that's Australian for Burger King, folks). Right on time, the Burger King himself would write me a birthday letter and send me a years worth of vouchers for a free sundae, fries, whopper junior or whatever. And during the month of my birthday I could go in and claim my birthday gift. A free Whopper! It was so exciting to a ten year old girl, back in a time when going out for a junk food dinner was a special treat to be savored, and dreamed about for another year.

Now however, it seems my birthdays are officially sponsored by the American Cancer Society.


No special birthday letter, no vouchers for free stuff (would I really want  ACS swag anyway?), instead just a winsome melody from the likes of Harry Connick Junior, a heartfelt bleating by Justin Bieber or even a comedic message from Jack Black.  All with faces that say "Aw, it's your birthday and you have cancer. Poor you."  Gosh, I can't wait.  (Editors Note: In case my facetiousness is not clear here, I don't want a special ACS-branded message for my birthday thanks!)

I'll be starting my day off right with a celebratory hit of chemotherapy. Perhaps I'll yell out "chemo for everyone!" and we'll pull up our IV poles, gather around my Lazy-Boy chair in the Lazy-Boy-Showroom-From-Hell, and sing a stirring rendition of Happy Birthday to me. (Proudly brought to you by the American Cancer Society).

I guess turning "41" generally passes without fanfare, a bit like "14", "23" and "32", plus all those other ages in between.  It's not really a milestone birthday like "1", "13", "16", "18", "21", "30" and then the BIG 4-0.  But "41" is  a gentle reminder to start fielding jokes about getting old and complaining about turning "50" all too soon.  Middle age beckons!

I've begun to count birthdays.  Seven birthdays since original diagnosis, four birthdays since a serious bump in the road, and two birthdays since we encountered a major pothole. Perhaps my turning "41" might be a considered a milestone of sorts by the statisticians, but I think I'd just as soon as not consider turning "41" a milestone, thank you very much.

I'd also love to start complaining about turning "50" and the onset of middle age.

And I'd also prefer my birthday wasn't an event worthy of sponsorship by a cancer organization, unless of course it involves a free hamburger.

Happy Birthday to me!

Whoot!

My 2nd Birthday!


My 4th Birthday.
Love my outfit!

Tuesday, May 10, 2011

My Girlish Dream

No shovel but a dream trip regardless. Egypt, April, 2005
When I was a kid I had big dreams for myself.  At the top of the list?  Archaeologist.  And me excavating a previously undiscovered ancient Egyptian tomb.  Whilst some kids were setting up lemonade stands in their front yards, I had a backyard museum.  It was full of things that I'd gone digging for in our garden.  I found some cool stuff too.  A little leather purse with pennies in it, broken bits of china, and okay maybe a couple of things swiped from my Dad's antiques collection.  Anyway if you wanted to see it, you had to pay the 10-cent entry fee.  I sat out there curating my museum all weekend.  I made about 50-cents thanks to my Dad's friends who generously indulged my silly childish fantasies. "Look but don't touch", I told them!

But as the years dragged on and I became slightly more cynical and, some might say realistic, my dreams changed.  I went from Archaeologist to Hospital Administrator.  I remember looking it up in my tenth grade book of careers.  Imagine being the boss of all those people?  The perfect job for the ultimate Leo and also strangely ironic with the benefit of hindsight.  I'm not sure what happened to that idea but it went by the wayside, along with another girlish dream of becoming a Librarian.  Who doesn't love the smell of old musty books?  Just ignore the nerd-alert at this point please!

Alas, instead of slugging it out in trenches of Ancient Egypt, I ended up becoming a public accountant.  Horribly boring and dull but it suited me down to the ground.  As you know from this blog,  I love a good data based rant any day of the week, and I never met an argument I didn't like, so really public accounting was the perfect situation for me.  I loved getting into the tax code, researching case law, writing argumentative memorandums and going fisty-cuffs with the tax auditors.  And then there was financial statement preparation.  Ahhh....blissful days of tabulating, analyzing, and collating.  I really did love it.

Then amidst my dream career, came breast cancer.  And nothing like a good dose of breast cancer treatment to put a major dent in your career, and indeed the visions for the rest of your life.

Now that I'm dealing with metastatic breast cancer, and undergoing a rather grueling treatment regimen, I find that my career options are somewhat limited.  Of course there's blogging which I seem to have taken to like a CPA jacked up on international tax code loopholes. And then there's the career that I never would have envisioned for myself in a gazillion years.

GUINEA PIG.


You see in chemotherapy drug development the process goes something like this:

Preclinical Screening


  • Animal and laboratory testing      
  • Can take 10-15+ years
  • ~40,000 chemicals screened each year; ~25% are selected for preclinical screening; ~10% are tested in phase I, human trials.


Phases of Clinical Trials:

  • Phase I:  Specific aim is to determine toxicity and maximum tolerated dose.
  • Phase II:  New drug is studied in a specific tumor type to determine response and further define toxicities.
  • Phase III: New drug or treatment is compared to standard therapy to determine superiority.
  • Phase IV: Post-marketing trials to further evaluate in larger numbers of patients.


From listening to prominent metastatic cancer researchers Pat Steeg and Danny Welch speak at the National Breast Cancer Coalition's recent conference, this is what I understood (and please readers feel free to chime in if my understanding is incorrect in any way).

I learned that chemotherapy drugs are almost always  developed using primary breast cancer tissues and then are tested in Phase I and II trials on metastatic cancer patients.  If the metastatic tumors remain fairly stable or shrink by a certain number, then the drug  moves to a randomized trial phase where "survival" is measured.  In the metastatic testing setting survival is measured in weeks or months and this is how "success" is defined.  From there the drug moves to next phase into the adjuvant setting and evaluated on a much larger group of patients.


It's only at the end of the drug development phase that any outright prevention of new metastasis is looked at and assessed.  BUT, for a drug to progress through the clinical trial phases, it must show that is has shrunk established metastatic tumors, NOT necessarily prevented new metastatic tumors.  In the words of Pat Steeg, "THIS IS STUPID!".    In the metastatic setting, the way the drug developments and approval phases are currently structured, drugs specifically designed to address metastasis, a biologically different animal to primary tumors, are destined to fail.  Because the aims of the drugs that the metastatic researchers like Danny and Pat are focusing on, are those that will induce metastatic tumor dormancy NOT necessarily shrink existing tumors.  Real prevention!

So just to recap.  My value to the drug development process right now, is as a guinea pig.  To have drugs tested on me, that are developed with the intention of treating earlier stage breast cancer.  Not specifically metastatic breast cancer.  The drugs may or may not work on me.  If they do work, most likely only for a finite period of time.    My outcome in treating my metastatic breast cancer is simply an (un)lucky by-product of the current drug development cycle.

Guinea pigs.  NOT GOOD ENOUGH.

I also learned from Pat Steeg that there IS a robust pipeline for secondary metastatic prevention drug trials.  But with the current structure for drug development and the associated incentives and funding costs, getting these drugs into clinical trials is a fight.  Besides bureaucratic red tape, the roadblocks to metastatic-specific drug development are immense.

We are entrenched in a breast cancer culture that favors research for primary and early stage breast cancer.  There is a dearth of metastatic breast cancer tissue available for research; most metastatic breast tumors are not biopsied because it's considered too invasive and unnecessary.  We don't know exactly how many people are living with metastatic disease as we are not officially counted anywhere.  How can the needs of our population be properly assessed and researched? Metastatic research is seen as to difficult and complex making funding grants hard to come by.   Big pharma must work to a business model to appease its shareholders, and metastatic cancer research is way down on the priority list because of the lead times and costs involved. And so the excuses pile up........

All of these roadblocks, yet around 30% of people receiving a breast cancer diagnosis are known to go on to develop metastatic disease(1).  And metastatic disease accounts for 90% of breast cancer mortality with around 40,000 deaths a year (2). And with less than 5% of cancer research funds spent globally on researching metastases (3), is it any wonder that, according to Danny Welch,  there are less than 1000 metastatic researchers worldwide?

How can we scream loudly enough that:

IF WE SOLVE THE RIDDLES OF METASTATIC BREAST CANCER THEN WE CAN ALMOST ELIMINATE MORTALITY FROM THIS DISEASE!

WHY THE ROADBLOCKS?

I'm not sure who coined the phrase first, but I've  been hearing it loud and clear from U.S. based metastatic breast cancer advocates like Musa Mayer of AdvancedBC.org, CJ Corneliussen-James  of MetaVivor and Ellen Moskowitz of Metastatic Breast Cancer Network.

What we need is this:





30% for 30%*
 
*30% (research funding)  for 30% (of the breast cancer population who will develop metastatic breast cancer)






Again I will quote Pat Steeg:  "Do we care enough to study mets?"

I certainly hope so, because I don't want to be an (angry) little guinea pig for the rest of my life. Well that's my girlish dream anyway.






(1) O'Shaughenssy, Oncologist 2005; 10(suppl 3):20-29
(2) Metastatic Breast Cancer Network
(3) J. Sleeman, P. Steeg, "Cancer metastasis as a therapeutic target", European Journal of Cancer 46 (2010) 1177-1180

Wednesday, May 4, 2011

No Awards Here

Last weekend I travelled to Washington D.C. to attend the National Breast Cancer Coalition's Advocacy Training Conference, along with over 800 other people interested in hearing more about the NBCC's bold mission to end breast cancer by 2020: "Breast Cancer Deadline 2020".

Can it be done?  Well the jury's still out on that question, but it's a start and we can't do any worse than where we already are. Click here to read  to read the NBCC's Breast Cancer Deadline 2020 publications,  including a baseline status report, their white paper on the mission, and a letter to scientists.  

This deadline represents a tangible goal to which this organization intends to be held accountable to.

In coming posts I will be sharing my reflections about the conference as well as other important information about things that we can all do to continue our efforts in helping to change the conversation about breast cancer, in order to bring about the paradigm shift that will be crucial to achieving the NBCC's goal of ending breast cancer by 2020.

So where does one start?


I was pondering this question, as I was on the train returning home and reading "Ending Breast Cancer: A Baseline Status Report".  Facts were jumping out at me and I began to feel overwhelmed. Here's a small sample.

90% of breast cancer deaths are due to metastasis. The incidence of women diagnosed with advanced breast cancer has not changed.  Rates of diagnosis of truly lethal disease have remained stable since 1975.  Mortality rates have not changed significantly. Forty thousand women and hundreds of men in the U.S. alone will die from breast cancer this year. The evidence of a mortality reduction from early detection is conflicting and still under question.  The efficacy of mammography as a screening tool remains a highly contentious issue.  Early detection is no guarantee that a later stage diagnosis can be prevented, nor that that a cancer will spread through metastasis at some later date.  Treatments to eradicate metastasis do no exist.  There is still SO much we don't know.




Lest I become too disheartened and simply fall into a heap crying "it's all too hard!" I decided to take a break from my reading, and go and hang out on Twitter for a bit.  Perhaps @BurbDoc could lighten my mood with his humorous rantings from #Suburbia.  Perhaps something like:



Suburban Physician
ACTUAL PATIENT QUOTE: "What do you mean no one prescribed quaaludes anymore?"


But it wasn't to be.  Instead I saw this:


Komen for the Cure (@komenforthecure)5/3/11 10:21 AM
CALL FOR ENTRIES: Submit your loved one to be named Komen #GlobalRace Survivor / Co-Survivor of the Year by 
5/8/11http://bit.ly/mFegAO
Blood pressure rising, the banshee scream beginning to curdle, but of course I had to click through.....

Susan G. Komen for the Cure®, the global leader in the fight against breast cancer, celebrates survivorship and we want you to as well. Please describe in 750 words or less why you or someone you know should be the 2011 Susan G. Komen Global Race for the Cure® Survivor or Co-Survivor of the Year. The Co-Survivor category recognizes someone who has gone above and beyond in support of a breast cancer survivor. To be eligible for either award and to submit a nomination, you must be a registered participant for the 2011 Komen Global Race for the Cure. Remember, 750 words or less for either category. The winning pair, to be selected by the 2011 Susan G. Komen for the Cure Executive Survivor Committee Task Force, will have demonstrated the greatest impact on their community as well as the global spirit of survival. 

************ FULL BANSHEE SCREAM ************

So Komen wants us to "celebrate survivorship" by nominating a  "2011 Susan G. Komen Global Race for the Cure® Survivor".

I guess the forty thousand women and hundreds of men who died last year of breast cancer won't be eligible.  Because they clearly didn't survive, and I guess that's an important criteria in order to receive this accolade.

Apparently the lucky recipients of this award "will have demonstrated the greatest impact on their community as well as the global spirit of survival."  I'm not really sure what all this means, but I'm wagering that "greatest impact on their community" has something to do with how much money the winners raised for Komen, and that their "global spirit of survival" at least means they are not dead.

After entertaining myself for a good few train journey miles about the blatant hilarious ridiculousness of the very notion of a "Survivor of the Year" award, I was left with the following thought.

Imagine if we acknowledged the truth about breast cancer and paid as much attention to the DEAD,  as we do to celebrating the so-called achievements of the mainstream breast cancer movement at all those pink parties and pink events, and handing out Survivor of the Year awards to those who revel in the "global spirit of survival".

Maybe, just maybe "Breast Cancer Deadline 2020" could be achieved.



A picture of me paying attention to the truth.
There were no awards handed out at this conference.
(Also this is not a product placement for Ocean Spray OJ ;) )


*********************************************************************************
Today's post is dedicated to Sarah, aka The Carcinista, who passed away yesterday of metastatic ovarian cancer at the age of 39.  If my posts read as a bit snarky, I owe it all to Sarah, whom I shall always remember as The Queen of Snark (with a Message).  On one of her last comments on my blog, she described my snark as "delicious".  No Sarah, you,  my friend,  were delicious.  Your wit, humor, sensitivity, smarts, and downright courage in the face of a terrifying beast will be remembered always.  Another shining bright light in the cancer blogosphere went out with the loss of the beautiful Sarah.  RIP.

(For more information and resources on ovarian cancer, please see this guest post by The Carcinista)